M&A - CERO THERAPEUTICS HOLDINGS, INC.

Form Type: 10-Q

Filing Date: 2025-05-15

Corporate Action: Merger

Type: Update

Accession Number: 000121390025044335

Filing Summary: Cero Therapeutics Holdings, Inc.'s quarterly report for the period ended March 31, 2025, includes significant updates regarding their financial performance post-merger. The report shows total current assets of $5,768,001 and total liabilities of $8,320,800, indicating a stockholders' deficit of $329,386. The statement highlights operational expenses totaling $4,950,531, primarily due to research and development costs of $2,907,827 and general administrative expenses of $2,042,704. The net loss for the quarter is reported at $5,105,931, leading to a comprehensive loss attributable to common shareholders of $5,454,158. The company also notes forward-looking statements related to future financial performance and drug candidate developments as part of their strategic objectives following the business combination that occurred in 2023. Key risks and uncertainties are acknowledged regarding the operational milestones and market responses to the business combination efforts.